BioWorld

April 8, 2003

ISTA Slides After FDA Issues 'Approvable' Letter On Vitrase

Although it's unclear at this point, the FDA may require a confirmatory study for ISTA Pharmaceuticals Inc.'s Vitrase, a single injection to the eye for vitreous hemorrhage. (BioWorld Today) Read More

Hemosol Laying Off All Staff As It Searches For Path Forward

Human, Murine Newborns Seem To Share Same Gene For Obesity, Hair, Wrinkles In Rare Disorder

Epigenomics Raises EUR21M To Fund Work In DNA Methylation

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...